Raymond James starts Omega with 'outperform' on cancer gene method
18/06/2024 13:53
** Shares of biotech company Omega Therapeutics OMGA.O
gain 11.83% to $2.08 premarket
** Raymond James starts coverage of the co with an
"outperform" rating, PT $12, citing Omega's new method to tackle
hard-to-treat cancer genes
** "Lead therapeutic OTX-2002 is the first programmable
epigenomic controller to reach the clinic," says the broker
** It adds that the co's platform, if proven in clinical
studies, could unlock a broad range of therapeutic opportunities
due to its targeting ability
** Among the 7 analysts that cover Omega Therapeutics Inc,
the breakdown of recommendations are 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell"
(Reporting by Jesus Calero)
((Jesus.calero@thomsonreuters.com))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence